BofA warns Fed risks policy mistake with early rate cuts
BOSTON—Tango Therapeutics, Inc. (NASDAQ:TNGX) Chief Financial Officer Daniella Beckman recently sold shares of the company as reported in a recent SEC filing. The transactions, which took place on February 4 and 5, involved the sale of a total of 8,232 shares of common stock, amounting to approximately $25,281. According to InvestingPro data, the stock has shown strong momentum with a 9.4% gain over the past week, despite trading significantly below its 52-week high of $12.80.
The shares were sold at a weighted average price, with transactions occurring within a range of $2.988 to $3.1614 per share. Following these sales, Beckman retains ownership of 150,284 shares of Tango Therapeutics. InvestingPro analysis shows the company maintains strong liquidity with a current ratio of 8.0, while five analysts have recently revised their earnings expectations upward.
These sales were executed as part of a "sell-to-cover" policy to satisfy tax withholding obligations related to the vesting of restricted stock units. The sales were automatic and not at Beckman’s discretion. For deeper insights into TNGX’s financial health and detailed analysis, including 10+ additional ProTips, check out the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Piper Sandler has expressed a positive outlook on the biopharmaceutical sector for the year 2025, particularly highlighting the potential for significant upside amid macroeconomic challenges. The firm anticipates robust merger and acquisition activity to continue strongly into 2025, along with the presence of numerous undervalued biotech companies. Argenx (NASDAQ:ARGX), with its strong commercial momentum of the product Vyvgart, and Neurocrine (NASDAQ:NBIX) Biosciences, with its favorable risk/reward profile attributed to the expansion of Ingrezza’s market reach, are among Piper Sandler’s top picks. The firm also pointed out the potential growth and optionality in Neurocrine Biosciences’ late-stage pipeline. These developments are part of a broader focus on companies with fundamental drivers that can offer long-term value in the biopharma industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.